2026-W46 · Nov 9–Nov 15 · Company · Profile · published
Abbott Laboratories company profile · business segments · history · financial snapshot · S&P 500 rank #68 · 雅培公司業務歷史財務與標普500地位
SNAPSHOT
| Ticker | ABT |
| Company | Abbott Laboratories |
| GICS sector / industry | Health Care (XLV) / Health Care Equipment |
| S&P 500 rank (by weight) | #68 · 0.26% (Oct 29, 2026) |
| Sector rank | #9 in Health Care (Oct 29, 2026) |
| Headquarters | Abbott Park, Illinois |
| Founded | 1888 |
| CEO | Robert B. Ford |
| Employees | Approximately 114,000 (Dec 31, 2024) |
| Market cap | $180.95B (Oct 30, 2026) |
| Share price | $106.20 (Oct 30, 2026 close) |
| SEC filings | EDGAR — CIK 0000001800 |
WHAT IT DOES
Abbott sells medical devices, diagnostics, nutritionals and branded generic pharmaceuticals worldwide.
Its diabetes care business, built around FreeStyle Libre continuous glucose monitors, is the largest growth engine.
Diagnostics spans laboratory, molecular and rapid tests, while nutritionals include Similac and Ensure.
BUSINESS SEGMENTS
| Established Pharmaceutical Products | Branded generic medicines sold mainly outside the United States. FY2024 net sales $5,194M. |
| Medical Devices | Diabetes care, cardiovascular and neuromodulation devices. FY2024 net sales $18,986M. |
| Diagnostics | Laboratory, molecular and rapid diagnostic tests. FY2024 net sales $9,341M. |
| Nutritionals | Pediatric and adult nutrition products including Similac and Ensure. FY2024 net sales $8,413M. |
HISTORY
| Year | Milestone |
|---|---|
| 1888 | Wallace C. Abbott founds the Abbott Alkaloidal Company in Chicago. |
| 1900 | The company incorporates as Abbott Laboratories. |
| 2013 | Abbott spins off its research-based pharmaceuticals business as AbbVie. |
| 2017 | Abbott completes the acquisitions of St. Jude Medical and Alere. |
COMPETITIVE POSITION
FINANCIAL SNAPSHOT
| Total revenue | $44.33B (FY2025 net sales) |
| Operating income | $8.05B (FY2025 operating earnings) |
| Net income | $6.52B (FY2025 net earnings) |
| Diluted EPS | $3.72 (FY2025 GAAP diluted EPS) |
KEY RISKS
WHY IT MATTERS FOR THE S&P 500
Abbott pairs a diversified health-care portfolio with a fast-growing diabetes platform: FreeStyle Libre gives the company a recurring sensor franchise, while nutritionals and diagnostics add cash-generating breadth. The risk is a single-product concentration in diabetes growth expectations.
SOURCES & METHODOLOGY
| Financials, segments, headquarters | Abbott Laboratories Form 10-K for the year ended December 31, 2024 (net sales $41.95B; operating earnings $6.83B; net earnings $13.40B; GAAP diluted EPS $7.64). |
| Index weight & ranks | Slickcharts S&P 500 weights, Oct 29, 2026 close, fetched Oct 30, 2026 |
| Market cap | $180.95B (Oct 30, 2026) |
| Logo | SPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics. |
| Chart | SPXSet chart library, monthly bars, compiled from Yahoo public information. |
Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com
FINANCIALS
公司快照
| 股票代號 | ABT |
| 公司 | 雅培實驗室 |
| GICS 板塊/行業 | 健康護理(XLV)/醫療保健設備 |
| 標普500排名(按權重) | #68 · 0.26%(Oct 29, 2026) |
| 板塊內排名 | 健康護理 #9(Oct 29, 2026) |
| 總部 | 伊利諾伊州亞培園 |
| 成立 | 1888 年 |
| 執行長 | 羅伯特·B·福特 |
| 員工 | 約 114,000 人(2024 年 12 月 31 日) |
| 市值 | $180.95B(Oct 30, 2026) |
| 股價 | $106.20(Oct 30, 2026 收盤) |
| SEC 申報 | EDGAR — CIK 0000001800 |
業務概覽
雅培在全球銷售醫療器械、診斷產品、營養品及品牌仿製藥。
其糖尿病護理業務以 FreeStyle Libre 連續血糖監測儀為核心,是最大的增長引擎。
診斷業務涵蓋實驗室、分子與快速檢測;營養品包括 Similac 與 Ensure。
業務板塊
| 成熟醫藥產品 | 主要在美國以外銷售的品牌仿製藥。 2024 財年淨銷售額 51.94 億美元。 |
| 醫療器械 | 糖尿病護理、心血管與神經調節器械。 2024 財年淨銷售額 189.86 億美元。 |
| 診斷 | 實驗室、分子與快速診斷檢測。 2024 財年淨銷售額 93.41 億美元。 |
| 營養品 | 包括 Similac 與 Ensure 的兒科與成人營養產品。 2024 財年淨銷售額 84.13 億美元。 |
歷史沿革
| 年份 | 里程碑 |
|---|---|
| 1888 年 | 華萊士·C·雅培在芝加哥創立 Abbott Alkaloidal Company。 |
| 1900 年 | 公司改組為 Abbott Laboratories。 |
| 2013 年 | 雅培分拆研究型製藥業務為 AbbVie。 |
| 2017 年 | 雅培完成收購聖猶達醫療(St. Jude Medical)與 Alere。 |
競爭地位
財務快照
| 總收入 | $44.33B(FY2025 淨銷售額) |
| 營業利潤 | $8.05B(FY2025 營業利潤) |
| 淨利潤 | $6.52B(FY2025 淨利潤) |
| 稀釋 EPS | $3.72(FY2025 GAAP 攤薄每股收益) |
主要風險
對標普500的重要性
雅培以多元化的醫療保健組合搭配快速增長的糖尿病平台:FreeStyle Libre 提供經常性感測器業務,營養品與診斷則帶來產生現金的廣度。風險在於糖尿病增長預期集中於單一產品線。
來源與方法
| 財務、板塊、總部 | 雅培截至 2024 年 12 月 31 日年度之 Form 10-K(淨銷售額 419.5 億美元;營業利潤 68.3 億美元;淨利潤 134.0 億美元;GAAP 攤薄每股收益 7.64 美元)。 |
| 指數權重與排名 | Slickcharts S&P 500 權重,Oct 29, 2026 收盤,Oct 30, 2026 抓取 |
| 市值 | $180.95B(Oct 30, 2026) |
| Logo | SPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。 |
| 股價圖 | SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。 |
來源:Yahoo Finance 月 K(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份)· SPXSet.com
財報
SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。
Entered 2026-10-30 05:17 · updated 2026-11-14 22:51 · rev 9